Literature DB >> 23332809

A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.

J Jornil1, T S Nielsen, I Rosendal, J Ahlner, A L Zackrisson, L W T Boel, B Brock.   

Abstract

We present a fatal drug poisoning case involving venlafaxine (VEN). The deceased took his medication regularly (including 150 mg VEN twice daily), and nothing in the case or autopsy findings pointed towards suicide. The toxicological assessment concluded that the cause of death was most likely due to a poisoning with a combination of VEN, oxycodone and ethanol, and the manner of death was considered to be an accident. The blood concentration of VEN was high (4.5mg/kg), and the ratio of the VEN metabolite O-desmethylvenlafaxine (ODV) to VEN was exceptionally low (0.006). Mechanistic pharmacokinetic simulations suggested that the low metabolite ratio was the result of combined poor metabolizer (PM) status of cytochrome P450 (CYP) 2C19 and CYP2D6. This hypothesis was confirmed by genetic analysis. Simulations revealed that it was likely that the combined missing CYP2D6 and CYP2C19 activity would cause higher concentrations of VEN, but the simulations also suggested that there could be additional reasons to explain the high VEN concentration found in this case. Thus, it seems likely that the potentially toxic VEN concentration was caused by reduced metabolic capacity. The simulations combined with genotyping were considered very useful in this fatal drug poisoning case.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23332809     DOI: 10.1016/j.forsciint.2012.12.020

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  7 in total

Review 1.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

2.  Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.

Authors:  C A Altar; J M Carhart; J D Allen; D K Hall-Flavin; B M Dechairo; J G Winner
Journal:  Pharmacogenomics J       Date:  2015-02-17       Impact factor: 3.550

3.  Rapid onset of syndrome of inappropriate antidiuretic hormone secretion induced by duloxetine in an elderly type 2 diabetic patient with painful diabetic neuropathy.

Authors:  Shinji Kamei; Hideaki Kaneto; Akihito Tanabe; Shintaro Irie; Yurie Hirata; Masashi Shimoda; Kenji Kohara; Tomoatsu Mune; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2014-12-29       Impact factor: 4.232

Review 4.  Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility.

Authors:  Joel G Winner; Bryan Dechairo
Journal:  Yale J Biol Med       Date:  2015-11-24

5.  Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.

Authors:  Sofia Garcia; Michael Schuh; Anvir Cheema; Herjot Atwal; Paldeep S Atwal
Journal:  Case Rep Genet       Date:  2017-10-16

6.  Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).

Authors:  Célia Lloret-Linares; Youssef Daali; Sylvie Chevret; Isabelle Nieto; Fanny Molière; Philippe Courtet; Florence Galtier; Raphaëlle-Marie Richieri; Sophie Morange; Pierre-Michel Llorca; Wissam El-Hage; Thomas Desmidt; Frédéric Haesebaert; Philippe Vignaud; Jerôme Holtzmann; Jean-Luc Cracowski; Marion Leboyer; Antoine Yrondi; Fabienne Calvas; Liova Yon; Philippe Le Corvoisier; Olivier Doumy; Kyle Heron; Damien Montange; Siamak Davani; Julien Déglon; Marie Besson; Jules Desmeules; Emmanuel Haffen; Frank Bellivier
Journal:  BMC Pharmacol Toxicol       Date:  2017-11-07       Impact factor: 2.483

Review 7.  Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain.

Authors:  Marta Vázquez; Natalia Guevara; Cecilia Maldonado; Paulo Cáceres Guido; Paula Schaiquevich
Journal:  Biomed Res Int       Date:  2020-08-13       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.